- Home
- AVTX vs CUE Comparison
AVTX vs CUE Comparison
Compare AVTX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- CUE
- Stock Information
- Founded
- AVTX 2011
- CUE 2014
- Country
- AVTX United States
- CUE United States
- Employees
- AVTX N/A
- CUE N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- CUE Health Care
- Exchange
- AVTX Nasdaq
- CUE Nasdaq
- Market Cap
- AVTX 138.8M
- CUE 59.5M
- IPO Year
- AVTX 2015
- CUE 2018
- Fundamental
- Price
- AVTX $11.33
- CUE $0.72
- Analyst Decision
- AVTX Strong Buy
- CUE Strong Buy
- Analyst Count
- AVTX 9
- CUE 2
- Target Price
- AVTX $30.14
- CUE $3.00
- AVG Volume (30 Days)
- AVTX 188.1K
- CUE 132.0K
- Earning Date
- AVTX 11-06-2025
- CUE 11-13-2025
- Dividend Yield
- AVTX N/A
- CUE N/A
- EPS Growth
- AVTX N/A
- CUE N/A
- EPS
- AVTX N/A
- CUE N/A
- Revenue
- AVTX $441,000.00
- CUE $8,286,000.00
- Revenue This Year
- AVTX N/A
- CUE N/A
- Revenue Next Year
- AVTX N/A
- CUE $13.27
- P/E Ratio
- AVTX N/A
- CUE N/A
- Revenue Growth
- AVTX N/A
- CUE N/A
- 52 Week Low
- AVTX $3.39
- CUE $0.45
- 52 Week High
- AVTX $16.00
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- AVTX 62.61
- CUE 34.73
- Support Level
- AVTX $9.54
- CUE $0.77
- Resistance Level
- AVTX $12.41
- CUE $0.78
- Average True Range (ATR)
- AVTX 1.05
- CUE 0.03
- MACD
- AVTX -0.10
- CUE -0.01
- Stochastic Oscillator
- AVTX 71.28
- CUE 9.53
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.